Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 12 May 2023 |
| Zealand Pharma Announces Financial Results for the First Quarter of 2023 | 11 May 2023 |
| Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight | 10 May 2023 |
| Total number of shares and voting rights in Zealand Pharma at April 28, 2023 | 28 Apr 2023 |
| Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | 25 Apr 2023 |
| Zealand Pharma launches long-term incentive program for Zealand's Board of Directors, Corporate Management and employees for 2023 | 19 Apr 2023 |